Eli Lilly and Co (LLY.N)

LLY.N on New York Stock Exchange

72.11USD
23 Jan 2015
Change (% chg)

$-0.02 (-0.03%)
Prev Close
$72.46
Open
$71.85
Day's High
$72.17
Day's Low
$71.06
Volume
787,318
Avg. Vol
1,275,559
52-wk High
$75.10
52-wk Low
$52.30

LLY.N

Chart for LLY.N

About

Eli Lilly and Company discovers, develops, manufactures, and sells products in two business segments human pharmaceutical products and animal health products. The Company manufactures and distributes its products through facilities in the United States, Puerto Rico and 11 other countries. Its animal health business, operating... (more)

Overall

Beta: 0.44
Market Cap(Mil.): $80,311.70
Shares Outstanding(Mil.): 1,113.43
Dividend: 0.50
Yield (%): 2.77

Financials

  LLY.N Industry Sector
P/E (TTM): 28.87 40.21 40.82
EPS (TTM): 2.50 -- --
ROI: 10.16 19.07 18.35
ROE: 15.57 19.85 19.25
Search Stocks

Lilly forecasts 2015 earnings, revenue shy of Street estimates

- Eli Lilly and Co forecast 2015 earnings and revenue just shy of market expectations as the drugmaker looks to bounce back after the expiration of patents on some of its biggest sellers.

07 Jan 2015

Lilly 2015 revenue forecast falls short of Wall St estimates

Jan 7 - Eli Lilly and Co, which has been battered in the past three years by competition from generics, forecast 2015 revenue shy of Wall Street expectations.

07 Jan 2015

BRIEF-Virbac closes Sentinel brands family acquisition Eli Lilly

* Announces closing of Sentinel brands family acquisition in United States from Eli Lilly

05 Jan 2015

Lilly to divest some Sentinel products to win approval on Novartis

WASHINGTON, Dec 22 - Eli Lilly and Co has won approval to buy Novartis AG's animal health unit on condition that it divest the Sentinel line of products for treating heartworm in dogs, the Federal Trade Commission said on Monday.

22 Dec 2014

Eli Lilly and Adocia agree to develop fast-acting insulin

PARIS - U.S. drugmaker Eli Lilly and French biotech Adocia said on Friday they agreed a worldwide licensing partnership to develop an ultra-rapid insulin to treat patients with Type 1 and Type 2 diabetes.

19 Dec 2014

Eli Lilly and Adocia agree to develop ultra-rapid insulin

PARIS, Dec 19 - U.S. drugmaker Eli Lilly and French biotech Adocia said on Friday they agreed a worldwide licensing partnership to develop ultra-rapid insulin to treat patients with Type 1 and Type 2 diabetes.

19 Dec 2014

Once-weekly Lilly diabetes drug wins EU approval

- The European Commission has granted marketing approval to Eli Lilly and Co's injectable Trulicity treatment for adults with type 2 diabetes, the U.S. drugmaker said on Tuesday.

25 Nov 2014

Once-weekly Lilly diabetes drug wins EU approval

Nov 25 - The European Commission has granted marketing approval to Eli Lilly and Co's injectable Trulicity treatment for adults with type 2 diabetes, the U.S. drugmaker said on Tuesday.

25 Nov 2014

Lilly, Boehringer revise terms of diabetes drugs alliance

- Eli Lilly and Co and German drugmaker Boehringer Ingelheim said they had revised the structure of their diabetes alliance for some countries.

29 Oct 2014

Lilly, Boehringer revise terms of diabetes drugs alliance

Oct 29 - Eli Lilly and Co and German drugmaker Boehringer Ingelheim said they had revised the structure of their diabetes alliance for some countries.

29 Oct 2014

Competitors

Earnings vs. Estimates

Analyst Research Reports

Report Title Price
Provider: Thomson Reuters Stock Report
$25.00
Provider: MacroRisk Analytics/EconomicInvestor
$25.00
Provider: Stock Traders Daily
$20.00
Provider: Wright Reports
$75.00
Provider: ValuEngine, Inc.
$25.00

NYSE and AMEX quotes delayed by at least 20 minutes. NASDAQ delayed by at least 15 minutes. For a complete list of exchanges and delays, please click here.

Search Stocks